Contact isolation versus standard precautions to decrease acquisition of extended-spectrum ?-lactamase-producing Enterobacterales in non-critical care wards: a cluster-randomised crossover trial - 19/06/20
, Frank Schwab, PhD a, Sonja Hansen, MD a, Carolina Fankhauser, MSc b, Stephan Harbarth, ProfMD b, Benedikt D Huttner, MD b, Cristina Diaz-Agero, MD c, Nieves Lopez, MD c, Rafael Canton, ProfPhD d, Patricia Ruiz-Garbajosa, PhD d, Hetty Blok, MSc e, Marc J Bonten, ProfPhD e, Fieke Kloosterman, DGN e, Joost Schotsman, MSc f, Ben S Cooper, ProfPhD g, Michael Behnke, PhD a, Jennifer Golembus a, Axel Kola, MD a, Petra Gastmeier, ProfMD aon behalf of the
R-GNOSIS WP5 study group
Summary |
Background |
The effectiveness of contact isolation for decreasing the spread of extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) has been questioned. The aim of this study was to establish the benefits of contact isolation over standard precautions for reducing the incidence density of ESBL-E colonisation and infection in adult medical and surgical wards with an active surveillance culture programme.
Methods |
We did a cluster-randomised crossover trial in adult wards in four European university hospitals. Medical, surgical, or combined medical–surgical wards without critical care were randomised to continue standard precautions alone or implement contact isolation alongside standard precautions for 12 months, followed by a 1 month washout period and 12 months of the alternate strategy. Randomisation was done via a computer-generated sequence, with a block size of two consecutive wards. Only laboratory technicians and data analysts were masked to allocation. Patients were screened for ESBL-E carriage within 3 days of admission, once a week thereafter, and on discharge. The primary outcome was the incidence density of ESBL-E, defined as the acquisition rate per 1000 patient-days at risk at the ward level and assessed in the per-protocol population, which included all patients screened at least twice with a length of stay of more than 1 week for each intervention period. No specific safety measures were assessed given the minimal risk of adverse events. The trial is registered, ISRCTN57648070.
Findings |
We enrolled 20 wards from four hospitals in Germany (eight wards), the Netherlands (four wards), Spain (four wards), and Switzerland (four wards). Between Jan 6, 2014, and Aug 31, 2016, 38 357 patients were admitted to these wards. Among 15 184 patients with a length of stay of more than 1 week, 11 368 patients (75%) were screened at least twice. The incidence density of ward-acquired ESBL-E was 6·0 events per 1000 patient-days at risk (95% CI 5·4–6·7) during periods of contact isolation and 6·1 (5·5–6·7) during periods of standard precautions (p=0·9710). Multivariable analysis adjusted for length of stay, percentage of patients screened, and prevalence in first screening cultures yielded an incidence rate ratio of 0·99 (95% CI 0·80–1·22; p=0·9177) for care under contact isolation compared with standard precautions.
Interpretation |
Contact isolation showed no benefit when added to standard precautions for controlling the spread of ESBL-E on non-critical care wards with extensive surveillance screening.
Funding |
European Commission.
Le texte complet de cet article est disponible en PDF.Plan
Vol 20 - N° 5
P. 575-584 - mai 2020 Retour au numéro
Article précédent
- Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
- Kelvin Kai-Wang To, Owen Tak-Yin Tsang, Wai-Shing Leung, Anthony Raymond Tam, Tak-Chiu Wu, David Christopher Lung, Cyril Chik-Yan Yip, Jian-Piao Cai, Jacky Man-Chun Chan, Thomas Shiu-Hong Chik, Daphne Pui-Ling Lau, Chris Yau-Chung Choi, Lin-Lei Chen, Wan-Mui Chan, Kwok-Hung Chan, Jonathan Daniel Ip, Anthony Chin-Ki Ng, Rosana Wing-Shan Poon, Cui-Ting Luo, Vincent Chi-Chung Cheng, Jasper Fuk-Woo Chan, Ivan Fan-Ngai Hung, Zhiwei Chen, Honglin Chen, Kwok-Yung Yuen
- PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study
- Sodiomon B Sirima, Laura Richert, Arnaud Chêne, Amadou T Konate, Cécilia Campion, Sébastien Dechavanne, Jean-Philippe Semblat, Nadine Benhamouda, Mathilde Bahuaud, Pierre Loulergue, Alphonse Ouédraogo, Issa Nébié, Moïse Kabore, Désiré Kargougou, Aïssata Barry, San Maurice Ouattara, Valérie Boilet, Florence Allais, Gwenaelle Roguet, Nicolas Havelange, Elvira Lopez-Perez, Alexis Kuppers, Eleine Konaté, Caroline Roussillon, Myriam Kanté, Linda Belarbi, Amidou Diarra, Noelie Henry, Issiaka Soulama, Amidou Ouédraogo, Helene Esperou, Odile Leroy, Frederic Batteux, Eric Tartour, Nicola K Viebig, Rodolphe Thiebaut, Odile Launay, Benoît Gamain
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?